Introduction
Lung cancer remains the leading cause of cancer deaths worldwide. 1 In the past few decades, lung cancer was binary classified into small-cell lung cancer and non-smallcell lung cancer (NSCLC). Nowadays, however, the discovery of the driver mutations and related target therapies has changed the way scientists and doctors are treating this disease. The 5-year survival rate of lung cancer remains low (only 16.8%) when taking all stages into account; 2 some selected patients still benefit a lot from targeted therapy.
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In NSCLC, the prevalence of KRAS mutation is 15%-32% according to the latest data. 9 The mutation frequency varies among different ethnic populations. A relatively low frequency is identified in Asian and Latin America populations (15%-20%) compared with European population (20%-30%). 10 This imbalance may partially attribute to the high frequency of EGFR mutation in Asian and Latin America populations, which are mutually exclusive with KRAS mutation, or other associated risk factors, such as tobacco use. Mutant KRAS gene is predominantly found in adenocarcinoma histology. In squamous histology tumors, it is a rare event. Many studies suggest that KRAS mutation is closely associated with cigarette smoking. 11 Current or former smokers have a higher frequency of KRAS mutations than never smokers. 11 Further analysis reveals that different smoking status leads to a different KRAS point mutation profile. Never smokers were significantly more likely than former or current smokers to have a transition mutation (G→A) rather than the transversion mutations known to be smoking-related (G→T or G→C; P,0.0001). 12 In 1990, Slebos et al first reported that KRAS codon 12 point mutation was a strong and unfavorable prognostic factor based on an analysis of 69 lung adenocarcinoma patients. 13 Since then, controversy remains on its prognostic significance for predicting the survival time in lung cancer. In 2005, a systematic review and meta-analysis revealed that KRAS mutation was of poor prognostic significance for survival in patients with NSCLC. Recently, a meta-analysis of 12 randomized trials confirmed that KRAS mutation was associated with poor prognosis for NSCLC, particularly for those with advanced stage disease or who received second or later line therapy or treated with EGFR TKIs. 14 Although many studies analyzed the prevalence, clinicopathological features, and prognosis of KRAS mutation, contradictory conclusions have appeared and controversy remains. [9] [10] [11] Besides, data from Asian population were insufficient. Therefore, here, we performed the largest retrospective study of KRAS mutation in patients with lung adenocarcinoma in an Asian ethnic group -to identify the prevalence of KRAS mutation in Chinese population, describe the clinicopathological features of these patients, and analyze their survival with other types of gene mutations.
Methods
Patients and samples
Patients were selected retrospectively at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center from 2007 to 2013. Patients who received neoadjuvant chemotherapy were excluded. All the qualified patients had primary lung cancer and received a radical resection. (Patients with stage I to stage III underwent complete surgical excision. As for stage IV patients, all of them had solitary or surgically resectable metastasis. Both the primary lesion and the metastasis were surgically removed through one or two surgeries). Two independent pathologists (Yuan Li and Xuxia Shen) pathologically confirmed their tumor samples as lung adenocarcinoma according to the new WHO classification of lung tumors. Tumor tissues and normal para-carcinoma tissues were sampled just after the surgical resection and immediately stored in liquid nitrogen.
This study was conducted in line with the Declaration of Helsinki and approved by the Institutional Review Board of the Fudan University Shanghai Cancer Center. Written informed consent was obtained from all patients to allow their biological samples to be genetically analyzed. The experimental protocol of this study was performed strictly in accordance to the guidelines.
rna extraction
Total RNA was extracted from the tumor and normal paracarcinoma tissue as per standard protocols (RNeasy Mini Kit, Qiagen, Hilden, Germany), respectively. Total RNA samples were reverse transcribed into complementary DNA using a Revert Aid First Strand cDNA Synthesis Kit (Fermentas, St Leon-Rot, Germany).
Mutation analysis
KRAS (exons 2-3), EGFR (exons [18] [19] [20] [21] [22] , HER2 (exons 18-21), and BRAF (exons [11] [12] [13] [14] [15] were amplified by polymerase chain reaction (PCR) using KOD-plus DNA polymerase and cDNAs. 15 (The primers are listed in Table S1 ). Direct dideoxynucleotide method sequencing was performed to analyze the gene mutations. A combined strategy of reverse transcriptase PCR and quantitative realtime PCR was performed to detect ALK, RET, and ROS1 fusions. Fluorescent in situ hybridization was used as a validation for these fusion genes.
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Clinicopathological features
Clinical information including sex, age at diagnosis, pathologic tumor-lymph node-metastasis stage (according to the seventh edition of the lung cancer staging classification system) tumor differentiation, and smoking status was collected. Histologic subtypes of adenocarcinoma were confirmed based on the newest International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society multidisciplinary classification of lung adenocarcinoma. Survival and tumor relapse information was collected every 3 or 6 months after surgery in the clinic or by telephone. 
Results
Clinicopathological features
A total of 1,368 patients from 2007 to 2013 were qualified in this retrospective study cohort. The average age was 59.7 years, ranging from 22.4 to 84.1 years. There were 623 (45.5%) males and 745 (54.5%) females. Of them, 369 were current smokers (27.0%), 79 were former smokers (5.8%), and 920 were never smokers (67.2%). The numbers of patients in pathological tumor-lymph node-metastasis stages I to IV were 749 (54.8%), 167 (12.2%), 425 (31.0%), and 27 (2.0%), respectively. In adenocarcinoma subtypes, acinar predominant (43.1%) was the most frequent, followed by solid predominant (18.6%), and papillary predominant (15.6%). More detailed clinicopathological features are summarized in Table 1 .
gene mutation spectrum
There were 837 patients who harbored EGFR mutation, accounting for approximately 60% of the population. KRAS mutation was detected in 113 (8.3%) of all the patients. Thirty-two (2.3%) patients had HER2 mutation, 20 (1.5%) patients had BRAF mutation, and 102 (7.5%) patients had ALK, RET, or ROS1 fusion genes ( Figure 1 ). No patients 
KRAS mutation subtypes
Nine different subtypes of KRAS mutation were identified, including five types of G12* mutations, two types of G13* mutations, and two types of Q61* mutations. G12C (GGT→TGT) was the most frequent amino acid substitution seen in this cohort, accounting for 33.6% of the patients followed by G12D (GGT→GAT) mutation (23.9%), G12V (GGT→GTT) mutation (22.1%), and G12A (GGT→GCT) mutation (7.1%). Seventy percent of patients (79/113) harbored transversion mutations (G12A, G12C, G12V, G13C, Q61H) ( Figure 2 ).
KRAS mutation and clinicopathological variables
In this study, KRAS mutation was more frequently found in male patients (odds ratio 5. 
Survival analysis of KRAS subtypes
In 108 qualified patients with KRAS mutation, the median RFS was 53 months, while the median overall survival was not reached. No significant difference was found in survival among patients with different KRAS point mutations. Sex ( Figure 4A and B), age ( Figure 4C and D), and smoking status ( Figure 4E and F) did not affect survival time either. Those patients with advanced stage or whose tumor was poorly differentiated got an earlier recurrence and shorter survival (Table 3) . Mutation sites in KRAS did not affect the prognosis ( Figure 5A and B). There was no difference in survival between patients with KRAS transition mutations and patients with KRAS transversion mutations ( Figure 5C and D). When the KRAS mutation was divided into two groups (hydrophobic 
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Discussion
In the present study, KRAS mutation was detected in 8.3% (113/1,368) of lung adenocarcinoma patients in Chinese population. This number was relatively lower compared with the data from Asian population. European population, however, had a much higher mutation rate of KRAS gene. 9, 10 Besides, KRAS mutation was predominantly found in male patients and smokers. KRAS mutation and other driver mutations, such as EGFR, HER2, and BRAF, were mutually exclusive. Poor differentiation appeared in almost half of the tumors with KRAS mutation, compared with less than a third of the non-KRAS mutant tumors. This suggested that KRAS mutation probably led to an unfavorable prognosis. Meanwhile, the proportion of invasive mucinous adenocarcinoma predominant subtype and solid predominant subtype was significantly higher in KRAS mutation. Considering these two subtypes, especially the solid predominant subtype as indicators of poor prognosis, KRAS mutation might be a late event in lung cancer. Keohavong et al 19 reported that specific KRAS point mutations (such as G12V) were associated with poorer outcome. Recently, a meta-analysis which synthesized 12 randomized trials also confirmed that KRAS mutations were related to poor survival benefit for NSCLC.
14 Our data, however, did not show this pattern in survival analysis.
KRAS point mutation in human cancers takes place primarily at residues G12, G13, or Q61, with single amino acid substitution. In lung cancer, KRAS mutation occurs predominantly at residues G12 or G13. 7, 9, 12 Mutations can be further divided into transversion and transition subtypes according to its biological features and prognostic impact. Riely's discovery of different smoking status leading to a different KRAS point mutation profile suggested that there might be an explicit mechanism of tobacco carcinogens on KRAS mutation. 12 Conflicting data also arouse the suspicion on cigarette smoke. 20 In animal experiments, scientists revealed quite a similar pattern in lung tumors from mice treated with BaP, 5-methylchrysene, and benzo [b] fluoranthene, which are carcinogens commonly found in tobacco smoke. 21 However, detailed analysis showed that the methylguanine pathway of nicotine-derived nitrosamine ketone, also known as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolic results in a high percentage of GGT→GAT mutations (transition) in codon 12 of KRAS, 22 while pyridyloxobutylation leads to more G→T mutation (transversion) in codon 12. 23 The relative significance of these pathways in human lung cells remains unknown, and further investigations are needed.
Remarkably, Ihle et al 24 classified KRAS mutation into hydrophobic (G12C and G12V) and hydrophilic alteration (G12D) subgroups. In vitro experiments demonstrated different patterns of downstream signal transduction and response to targeted therapies between these two subgroups. Specifically, mutant G12C or G12V KRAS protein would activate Ral signaling and decrease growth factor-dependent Akt activation, while mutant G12D KRAS protein would predominantly activate the PI3K and MEK/ERK pathways. Such results could be partially explained by the changes in spatial conformation after mutation. Finally, tumor behavior and drug sensitivity varied in different subgroups of KRAS mutation. 25 Although in general, KRAS codon 12 point mutation was proven to indicate a poor prognosis, a more specific classification was required to assess its biological malignancy and therapeutic efficacy. In clinical practice, individualized treatment was recommended concerning patients harboring KRAS mutation.
Nowadays, scientists also focus on KRAS mutation cooccurring with other gene mutations. Lung adenocarcinomas harboring STK11/LKB1, TP53, or CDKN2A/B mutation as well as KRAS mutation identified distinct clinicopathological features and different therapeutic responses. 26 This insight would direct the treatment strategy not only pointing at a single KRAS gene, but a set of related genes.
There are no known direct KRAS targeted agents. Survival of patients harboring KRAS mutation is almost disappointing with or without chemotherapy, targeted therapy, or other treatment. Some researchers came to a conclusion that KRAS status might indicate poor response to EGFR TKIs. [27] [28] [29] [30] [31] This evidence should be considered with caution due to the small numbers involved in the analyses. Meanwhile, meta-analysis showed that KRAS mutations are highly specific negative predictors of response to single-agent EGFR TKIs in advanced NSCLC. 32 Limited success was developed on the treatment of KRAS mutation in the past decade; however, delightful consequences emerged.
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KRAS mutation in chinese lung adenocarcinoma treated advanced KRAS-mutant NSCLC. 33 Patients in the experiment group had a longer progression-free survival and 37% of them had an objective response.
By blocking one of the most important downstream pathways of KRAS, an MEK1/2 inhibitor (AZD6244) combined with cisplatin showed an antitumor effect in KRAS-dependent lung cancer cells and animal models. 34 Clinical studies of applications of MEK1/2 inhibitors in cisplatin-based chemotherapy for lung cancer patients harboring KRAS mutation are urgently required.
Ostrem et al 35 developed a small molecule that irreversibly bound to a common oncogenic mutant, K-Ras (G12C), while it had no effect on the wild-type protein.
Once bound, the inhibitor-KRAS compound subverted the native nucleotide preference to favor GDP over GTP and therefore impaired binding to the downstream Raf protein.
If it is possible to make this molecule available in clinics in the future, it will make KRAS mutation targetable and may bring benefit to patients.
Furthermore, oncogenic drivers, such as mutated KRAS can be targeted with synthetic lethality approaches. 36 Although synthetic lethality till now is a concept and has not yet been applied in clinical practice, it is a promising rationale and will ultimately become a therapeutic approach.
Conclusion
In Chinese population, we identified KRAS mutation in 8.3% (113/1,368) of the patients with lung adenocarcinoma. KRAS mutation defines a molecular subset of lung adenocarcinoma with unique clinicopathological features. KRAS mutations were more frequent in male patients, former/current smokers, and patients harboring KRAS mutations who showed poor differentiation in tumor tissues.
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